10.31.13
AstraZeneca
3Q Revenues: $6.3 billion (-6%)
3Q Earnings: $1.2 billion (-27%)
YTD Revenues: $20.7 billion (-9%)
YTD Earnings: $3.1 billion (-26%)
Comments: The impact from products that recently lost exclusivity is estimated at $350 million in the quarter. U.S. revenues were down 8% with declines in Crestor (-11% to $1.4 billion) and Nexium (-5% to $918 million), partially offset by growth for Symbicort (+7% to $839 million), the diabetes franchise, FluMist (+30% to $188 million) and Brilinta/Brilique (+208% to $75 million). The negative impact of U.S healthcare reform in the quarter was approximately $199 million. Rest of World (ROW) revenue was down 2% related to the loss of exclusivity for Atacand (-35% to $143 million), Nexium, and Seroquel IR (-47% to $84 million), combined with generic competition for Seroquel XR (-10% to $339 million), partially offset by revenue increases for Brilique and the diabetes franchise.
3Q Revenues: $6.3 billion (-6%)
3Q Earnings: $1.2 billion (-27%)
YTD Revenues: $20.7 billion (-9%)
YTD Earnings: $3.1 billion (-26%)
Comments: The impact from products that recently lost exclusivity is estimated at $350 million in the quarter. U.S. revenues were down 8% with declines in Crestor (-11% to $1.4 billion) and Nexium (-5% to $918 million), partially offset by growth for Symbicort (+7% to $839 million), the diabetes franchise, FluMist (+30% to $188 million) and Brilinta/Brilique (+208% to $75 million). The negative impact of U.S healthcare reform in the quarter was approximately $199 million. Rest of World (ROW) revenue was down 2% related to the loss of exclusivity for Atacand (-35% to $143 million), Nexium, and Seroquel IR (-47% to $84 million), combined with generic competition for Seroquel XR (-10% to $339 million), partially offset by revenue increases for Brilique and the diabetes franchise.